Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals' stock experienced a 30% drop in October 2025 following ESMO data, but H.C. Wainwright reiterated a "Buy" rating. In August 2025, the stock gained 16.19% after reporting Q2 results. November 2025 saw a $190 million public offering, closing at $218.5 million. The stock reached a 52-week high in December 2025. Analysts reaffirmed "Buy" ratings in January 2026, raising price targets. A 2.9% stock drop occurred after the CFO's departure in late January 2026. Insider stock sales also took place in January 2026. Over the past year, the stock price has increased by approximately 320.9%.

Demand seasonality is not applicable to Olema Pharmaceuticals. Demand for its products is driven by clinical trial progress, regulatory approvals, market adoption, the incidence and prevalence of breast cancer, and the efficacy and safety profile of its therapies.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers, particularly ER+/HER2- advanced or metastatic breast cancer. Their lead product candidate, Palazestrant (OP-1250), is in Phase 3 clinical trials and has received FDA Fast Track designation. OP-3136, another product candidate, is in Phase 1 clinical trials.

Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, and has operations in Cambridge, Massachusetts. The company plans to expand into new markets in Europe and Asia by 2024.

Olema Pharmaceuticals generally has a positive brand reputation, scoring higher than 74% of companies in the medical sector. Analyst ratings are predominantly "Moderate Buy" or "Strong Buy." However, the stock drop following the ESMO data presentation and the CFO's departure, along with insider stock sales, could have temporarily impacted its reputation.

Olema Pharmaceuticals, Inc. has 248 institutional owners holding 72,713,782 shares, including major holders like Bain Capital Life Sciences Investors, LLC, and BlackRock, Inc. Individual insiders hold approximately 3.07% of the shares, with recent transactions involving share sales by directors and senior executives.